Small lab-made molecules aimed at brain tumors run into problems
Original title: Approaches to optimize cell internalization and in vivo tumor homing by aptamer-drug conjugates using SELEX
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This is early lab and animal work, and it has not been tested in people.
The short version
Scientists tried to build tiny molecules that carry drugs into brain tumor cells, and they hit setbacks.
What was studied. This report is about aptamers. Aptamers are short, folded strands of RNA or DNA that stick to a target. The team used a lab method called SELEX to find aptamers that home in on glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, and to link them to drugs.
What they found. The team had already made anti-tumor aptamers with this method. These aptamers are six-fold smaller in mass than antibodies. Here the team tried to steer the search toward aptamers that get taken inside tumor cells. That effort ran into trouble. The aptamers lost their ability to stick to the tumor and not to healthy tissue.
What this means, and what it doesn't
What it could mean: glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary is hard to treat, in part because drugs struggle to cross into the brain. Small aptamers are one idea for getting drugs in. This report is honest about a problem the researchers still need to solve.
What it doesn't mean: This does not mean a new treatment is coming soon. This is early lab and animal work, not a test in people. No patient was treated here. The report describes a setback, not a success. It is not a cure, and it is not something a doctor can offer you today.
Source: bioRxiv (preprint), August 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.